Search research articles
Contact Us
Filters
Showing results (51-60 of 63) with videos related to
Page
of 7
Sort By:
Journal of Clinical Lipidology
|
March 29, 2022
Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials
Ulrich Laufs, Christie M Ballantyne, Maciej Banach, et al.
Lancet (London, England)
|
May 10, 2025
Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial
Ashish Sarraju, Danielle Brennan, Kierstyn Hayden, et al.
Journal of the American Heart Association
|
June 23, 2026
Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid
G B John Mancini, A Michael Lincoff, Anne C Goldberg, et al.
Journal of Clinical Lipidology
|
May 24, 2011
Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia
Anne C Goldberg, Paul N Hopkins, Peter P Toth, et al.
Journal of the American College of Cardiology
|
November 19, 2013
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Neil J Stone, Jennifer G Robinson, Alice H Lichtenstein, et al.
Journal of Clinical Lipidology
|
May 24, 2011
Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia
Anne C Goldberg, Paul N Hopkins, Peter P Toth, et al.
Frontiers in Health Services
|
May 15, 2023
Designing implementation strategies to improve identification, cascade testing, and management of families with familial hypercholesterolemia: An intervention mapping approach
Laney K Jones, Evan M Calvo, Gemme Campbell-Salome, et al.
Journal of Clinical Lipidology
|
February 25, 2026
Update on familial hypercholesterolemia: An expert clinical consensus from the National Lipid Association
Zahid Ahmad, Anandita Agarwala, Marina Cuchel, et al.
American Heart Journal
|
May 5, 2024
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN
Stephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
Nature Medicine
|
April 17, 2026
Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial
Stephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 63) with videos related to
Sort By:
Page
of 7
Journal of Clinical Lipidology
|
March 29, 2022
Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials
Ulrich Laufs, Christie M Ballantyne, Maciej Banach, et al.
Lancet (London, England)
|
May 10, 2025
Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial
Ashish Sarraju, Danielle Brennan, Kierstyn Hayden, et al.
Journal of the American Heart Association
|
June 23, 2026
Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid
G B John Mancini, A Michael Lincoff, Anne C Goldberg, et al.
Journal of Clinical Lipidology
|
May 24, 2011
Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia
Anne C Goldberg, Paul N Hopkins, Peter P Toth, et al.
Journal of the American College of Cardiology
|
November 19, 2013
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Neil J Stone, Jennifer G Robinson, Alice H Lichtenstein, et al.
Journal of Clinical Lipidology
|
May 24, 2011
Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia
Anne C Goldberg, Paul N Hopkins, Peter P Toth, et al.
Frontiers in Health Services
|
May 15, 2023
Designing implementation strategies to improve identification, cascade testing, and management of families with familial hypercholesterolemia: An intervention mapping approach
Laney K Jones, Evan M Calvo, Gemme Campbell-Salome, et al.
Journal of Clinical Lipidology
|
February 25, 2026
Update on familial hypercholesterolemia: An expert clinical consensus from the National Lipid Association
Zahid Ahmad, Anandita Agarwala, Marina Cuchel, et al.
American Heart Journal
|
May 5, 2024
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN
Stephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
Nature Medicine
|
April 17, 2026
Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial
Stephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
Page
of 7